| Expression pattern: |
UP |
| Associated gene: |
YAP, mut-p53, TEAD1, Pol II, aurka, mki67, bub1 |
| Associated microRNA: |
miR-497-5p |
| Biological function: |
Acts as an oncogene promoting malignant phenotype and proliferation/colony formation; contributes to cisplatin resistance. |
| Molecular mechanism: |
Transcriptionally enhanced by mut-p53/YAP/TEAD complex; binds YAP and may autoregulate its own expression; directly regulates miR-497-5p via a binding site, affecting downstream proliferation genes (aurka, mki67, bub1). |
| Biological pathway or process: |
proliferation (promotes); cell cycle (promotes); ceRNA regulation (promotes); chemoresistance (promotes); Hippo/YAP (other) |
| Detected method: |
Q
|
| Validation methods: |
divergent primers PCR; RT-qPCR; Sanger Sequencing; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; RIP (RNA Immunoprecipitation); ChIP / ChIP-seq; Transfection; Cell Cycle Assay; Colony Formation Assay; Flow Cytometry（Non-apoptosis/cycle）; Bioinformatics Analysis; Survival Analysis; Western Blot |
| Clinical significance: |
High circPVT1 levels are associated with poorer overall survival, dependent on TP53 mutations. |
| Description: |
In HNSCC, circPVT1 is up-regulated (especially in TP53-mutant tumors) and promotes malignant phenotypes such as proliferation and colony formation, and contributes to cisplatin resistance. Mechanistically, it is transcriptionally activated by the mut-p53/YAP/TEAD complex, binds YAP (supporting an autoregulatory loop), and represses miR-497-5p to increase proliferation-associated genes (e.g., aurka, mki67, bub1). High circPVT1 expression is associated with poorer overall survival. |
| Confidence score: |
0.8267 |